J Sastre

Summary

Country: Spain

Publications

  1. doi request reprint Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables
    J Sastre
    Department of Medical Oncology, Hospital Clinico San Carlos de Madrid, Madrid, Spain
    Ann Oncol 19:935-8. 2008
  2. doi request reprint First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)
    J Sastre
    HC San Carlos, Madrid, Center affíliated to the Red Temática de Investigación Cooperativa RD06 0020 0021, Instituto Carlos III, Spanish Ministry of Science and Innovation, Spain
    Crit Rev Oncol Hematol 77:78-84. 2011
  3. doi request reprint First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours
    J Sastre
    Medical Oncology Department, Hospital Clinico San Carlos, c Martin Lagos s n, 28040 Madrid, Spain Electronic address
    Eur J Cancer 51:1371-80. 2015
  4. pmc Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study
    Marta Martin-Richard
    Medical Oncology Department, Hospital de la Santa Creu y Sant Pau, Av, Sant Antoni Mª Claret, 167, Barcelona 08025, Spain
    BMC Cancer 13:427. 2013
  5. doi request reprint Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab
    Javier Sastre
    Medical Oncology Department, HC San Carlos, Madrid, Spain Center affiliated with the Red Temática de Investigación Cooperativa RD06 0020 0021, Instituto Carlos III, Spanish Ministry of Science and Innovation, Madrid, Spain Electronic address
    Clin Colorectal Cancer 12:280-6. 2013
  6. pmc Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior
    Beatriz Perez-Villamil
    Molecular Oncology Laboratory, Medical Oncology Department, Hospital Clinico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos IdISSC, c Martin Lagos s n, Madrid, 28040, Spain
    BMC Cancer 12:260. 2012
  7. pmc Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study
    Javier Sastre
    Medical Oncology Department, HC San Carlos, Madrid, Spain
    Oncologist 17:947-55. 2012
  8. pmc First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study
    Javier Sastre
    Medical Oncology Department, Hospital Clinico San Carlos, Calle Martín Lagos s n 28040 Madrid, Spain
    Oncologist 17:339-45. 2012
  9. pmc Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients
    Guillermo Gervasini
    Department of Pharmacology and Psychiatry, University of Extremadura, Badajoz, Spain
    BMC Cancer 7:118. 2007
  10. pmc Chemotherapy for gastric cancer
    Javier Sastre
    Servicio de Oncologia Medica, HCU San Carlos, c Martin Lagos s n 28040 Madrid, Spain
    World J Gastroenterol 12:204-13. 2006

Detail Information

Publications67

  1. doi request reprint Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables
    J Sastre
    Department of Medical Oncology, Hospital Clinico San Carlos de Madrid, Madrid, Spain
    Ann Oncol 19:935-8. 2008
    ..Few data have been published concerning the role of CTCs detection by this method in colorectal cancer. The aim of this study was to correlate the presence of CTCs with the commonest clinical and morphological variables...
  2. doi request reprint First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)
    J Sastre
    HC San Carlos, Madrid, Center affíliated to the Red Temática de Investigación Cooperativa RD06 0020 0021, Instituto Carlos III, Spanish Ministry of Science and Innovation, Spain
    Crit Rev Oncol Hematol 77:78-84. 2011
    ..to evaluate the efficacy and safety of first-line single-agent cetuximab in fit elderly patients with metastatic colorectal cancer, as well as potential molecular predictive factors for efficacy...
  3. doi request reprint First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours
    J Sastre
    Medical Oncology Department, Hospital Clinico San Carlos, c Martin Lagos s n, 28040 Madrid, Spain Electronic address
    Eur J Cancer 51:1371-80. 2015
    ..Monotherapy with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies may be an option for these patients with few systemic toxic effects...
  4. pmc Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study
    Marta Martin-Richard
    Medical Oncology Department, Hospital de la Santa Creu y Sant Pau, Av, Sant Antoni Mª Claret, 167, Barcelona 08025, Spain
    BMC Cancer 13:427. 2013
    ..This is the first prospective study investigating tumour stabilisation with the long-acting SSA lanreotide Autogel in patients with progressive NETs...
  5. doi request reprint Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab
    Javier Sastre
    Medical Oncology Department, HC San Carlos, Madrid, Spain Center affiliated with the Red Temática de Investigación Cooperativa RD06 0020 0021, Instituto Carlos III, Spanish Ministry of Science and Innovation, Madrid, Spain Electronic address
    Clin Colorectal Cancer 12:280-6. 2013
    ..In this post hoc analysis of the MACRO trial, the potential additive effect of these 2 factors on patient outcomes was explored...
  6. pmc Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior
    Beatriz Perez-Villamil
    Molecular Oncology Laboratory, Medical Oncology Department, Hospital Clinico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos IdISSC, c Martin Lagos s n, Madrid, 28040, Spain
    BMC Cancer 12:260. 2012
    ....
  7. pmc Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study
    Javier Sastre
    Medical Oncology Department, HC San Carlos, Madrid, Spain
    Oncologist 17:947-55. 2012
    ..An ancillary study was conducted to evaluate the circulating tumor cell (CTC) count as a prognostic and/or predictive marker for efficacy endpoints...
  8. pmc First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study
    Javier Sastre
    Medical Oncology Department, Hospital Clinico San Carlos, Calle Martín Lagos s n 28040 Madrid, Spain
    Oncologist 17:339-45. 2012
    ..Single-agent cetuximab is safe and active in elderly patients with advanced colorectal cancer (CRC). A cetuximab-capecitabine combination has not previously been tested in elderly patients with advanced CRC...
  9. pmc Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients
    Guillermo Gervasini
    Department of Pharmacology and Psychiatry, University of Extremadura, Badajoz, Spain
    BMC Cancer 7:118. 2007
    ..This study aims to examine associations between common CYP3A4 and CYP3A5 polymorphisms and digestive cancer risk...
  10. pmc Chemotherapy for gastric cancer
    Javier Sastre
    Servicio de Oncologia Medica, HCU San Carlos, c Martin Lagos s n 28040 Madrid, Spain
    World J Gastroenterol 12:204-13. 2006
    ..Neoadjuvant chemotherapy or chemoradiation therapy remains experimental, but several phase II studies are showing promising results. Phase III trials are needed...
  11. doi request reprint Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study
    Javier Sastre
    Servicio de Oncologia Medica, Hospital Clinico San Carlos, 28040 Madrid, Spain
    Crit Rev Oncol Hematol 70:134-44. 2009
    ..This analysis compares the outcomes of first-line oxaliplatin plus fluoropyrimidines in elderly versus young patients...
  12. ncbi request reprint UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors
    Javier Sastre
    Servicio de Oncologia Medica, Hospital Clinico San Carlos, Madrid, Spain
    Anticancer Drugs 17:417-21. 2006
    ..Eight out of 13 patients (61.5%) with metastatic colorectal cancer achieved stable disease. UFT plus oxaliplatin is a feasible and safe combination. A phase II trial in first-line advanced colorectal cancer is ongoing...
  13. ncbi request reprint Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study
    Javier Sastre
    Servicio de Oncologia Medica, Hospital Clinico San Carlos, c Profesor Martín Lagos, S N, 28040 Madrid, Spain
    J Clin Oncol 23:3545-51. 2005
    ..This study was performed to determine the efficacy and safety of irinotecan (CPT-11) in combination with fluorouracil (FU) administered as a 48-hour continuous infusion twice a month in elderly patients...
  14. ncbi request reprint Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer
    Javier Sastre
    Department of Medical Oncology, Hospital Clinico San Carlos, 28040 Madrid, Spain
    Anticancer Drugs 22:185-90. 2011
    ..Three-year disease-free survival compares favourably with historical controls, especially in those patients with high risk factors for relapse.Phase III controlled trials are needed...
  15. ncbi request reprint A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours
    Javier Sastre
    Servicio de Oncologia Medica, Hospital Clinico San Carlos de Madrid, Madrid, Spain
    Cancer Chemother Pharmacol 55:453-60. 2005
    ..5-FU. This phase I pharmacokinetic and clinical study evaluated escalating CPT-11 doses administered every 3 weeks combined with a fixed dose of 5-FU CI over 14 days to find the maximum tolerated dose (MTD) of this combined chemotherapy...
  16. ncbi request reprint 5-fluorouracil as a protracted continuous infusion plus irinotecan (CPT-11) in patients with advanced colorectal cancer treated with fluoropyrimidine-based regimens as first line
    Javier Sastre
    Servicio de Oncologia Medica, Hospital Clinico San Carlos, Madrid, Spain
    Anticancer Drugs 14:543-7. 2003
    ..We conclude that protracted 5-FU infusion plus CPT-11 is an active and safe regimen for patients with advanced CRC. A phase III trial comparing this schedule with conventional CPT-11 monotherapy is warranted...
  17. ncbi request reprint Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors
    E Diaz-Rubio
    Department of Oncology, Hospital Clinico Universitario San Carlos, Madrid, Spain
    Ann Oncol 13:558-65. 2002
    ..v. oxaliplatin. Secondary objectives included evaluation of the safety profile and antitumor activity...
  18. ncbi request reprint PAZONET: A phase II trial of pazopanib in patients with metastatic neuroendocrine tumors (NETs) who may have previously received antiangiogenic or mTOR treatment
    J Capdevila
    Vall d Hebron University Hospital, Barcelona, Spain IDIBELL, Institut Català d Oncologia L Hospitalet, Barcelona, Spain Hospital Universitario 12 de Octubre, Madrid, Spain Hospital Clínico San Carlos, Madrid, Spain Hospital Universitario Virgen del Rocío Instituto de Biomedicina de Sevilla IBIS, Sevilla, Spain Hospital Universitario Virgen de la Victoria, Malaga, Spain START Madrid, Centro Integral Oncologico Clara Campal, Madrid, Spain Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain Hospital Universitario Son Espases, Mallorca, Spain Hospital Ramon y Cajal, Madrid, Spain
    J Clin Oncol 29:TPS171. 2011
    ..Previous activity of pazopanib in advanced gastroenteropancreatic NETs has been reported (Phan et al. ASCO 2010). No data is available of the activity of pazopanib after tumor progression to prior anti-VEGF or mTOR treatment...
  19. ncbi request reprint Circulating tumor cells in locally advanced breast cancer
    J A Garcia-Saenz
    Clinico San Carlos Universitary Hospital, Madrid, Spain
    J Clin Oncol 27:e22159. 2009
    ....
  20. ncbi request reprint Cetuximab and capecitabine as first-line treatment for elderly patients (pts) with metastatic colorectal cancer (mCRC): Preliminary results of TTD trial
    C Gravalos
    Hospital 12 de Octubre, Madrid, Spain Hospital Marqués Valdecilla, Santander, Spain Hospital General, Alicante, Spain Hospital Clinico Universitario San Carlos, Madrid, Spain Hospital Santa Creu i Sant Pau, Barcelona, Spain Complejo Hospitalario Juan Canalejo, La Coruna, Spain Hospital Regional Universitario Carlos Haya, Malaga, Spain Institute of Oncology Hospital Germans Trias I Pujol, Badalona, Spain Hospital Clinico Universitario San Carlos, Madrid, Spain Hospital Reina Sofía, Cordoba, Spain
    J Clin Oncol 26:15027. 2008
    ..Now we are doing this trial to determine the efficacy and tolerance of Cetuximab in combination with Capecitabine...
  21. doi request reprint Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions
    Ana Custodio
    Department of Medical Oncology, Hospital Universitario Clinico San Carlos, Madrid, Spain
    Cancer Treat Rev 35:676-84. 2009
    ..The main goal of this paper is reviewing this topic...
  22. ncbi request reprint Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?
    P Garcia-Alfonso
    Medical Oncology Department, Gregorio Marañón University Hospital Center Affiliated to the Red Tematica de Investigacion Cooperativa en Cancer RTICC, Instituto Carlos III, Spanish Ministry of Science and Innovation, Madrid, Spain
    Clin Transl Oncol 18:1072-1081. 2016
    ..Additionally, the magnitude of the clinical benefit provided by regorafenib to these patients has been explored and whether there are poorer outcomes in certain subpopulations...
  23. ncbi request reprint Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801)
    D E Castellano
    Hospital Universitario 12 de Octubre, Madrid, Spain Vall d Hebron University Hospital, Barcelona, Spain Institut Catala d Oncologia, Barcelona, Spain Hospital Clínico San Carlos, Madrid, Spain Hospital Miguel Servet, Zaragoza, Spain Canarias, Tenerife, Spain Hospital Universitario Virgen del Rocío Instituto de Biomedicina de Sevilla IBIS, Sevilla, Spain University Hospital Germans Trias i Pujol ICO, Barcelona, Spain Hospital Universitario Virgen de la Victoria, Malaga, Spain START Madrid, Centro Integral Oncologico Clara Campal, Madrid, Spain
    J Clin Oncol 29:4113. 2011
    ..S+B combination has shown manageable toxicity in phase I trials in solid tumors. The aim of this study was to evaluate the efficacy and toxicity of the STI's combination in NETs...
  24. ncbi request reprint Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer
    E Aranda
    Servicio de Oncologia Medica, Hospital Universitario Reina Sofia, Cordoba, Spain
    Ann Oncol 15:559-67. 2004
    ..v.) infusion] combined with 5-fluorouracil (5-FU 3 g/m(2) weekly 48 h i.v. infusion, TTD regimen) as first-line chemotherapy for patients with advanced colorectal cancer (CRC)...
  25. doi request reprint Recombinant lipid transfer protein Tri a 14: a novel heat and proteolytic resistant tool for the diagnosis of baker's asthma
    A Palacin
    Unidad de Bioquimica, Departamento de Biotecnologia, E T S Ingenieros Agronomos, Madrid, Spain
    Clin Exp Allergy 39:1267-76. 2009
    ..Wheat lipid transfer protein (LTP) Tri a 14 is a major allergen associated with wheat allergy. No panel of wheat recombinant allergens for component-resolved diagnosis of baker's asthma is currently available...
  26. doi request reprint Irinotecan-cetuximab-bevacizumab as a salvage treatment in heavily pretreated metastatic colorectal cancer patients: a retrospective observational study
    J Feliu Batlle
    Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain
    Chemotherapy 57:138-44. 2011
    ..The objective was to evaluate the efficacy of irinotecan-cetuximab-bevacizumab in combination as a salvage treatment for heavily pretreated metastatic colorectal cancer patients...
  27. ncbi request reprint Increased prostaglandin E2 levels in the airway of patients with eosinophilic bronchitis
    B Sastre
    Immunology Department Fundación Jiménez Díaz Capio, CIBERES ISCIII, Madrid, Spain
    Allergy 63:58-66. 2008
    ....
  28. ncbi request reprint Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer
    R Hitt
    Hospital 12 de Octubre, Madrid, Spain Hospital Clinic Barcelona, Barcelona, Spain Hospital San Pablo Barcelona, Barcelona, Spain Spanish Head and Neck Cancer Group, Valencia, Spain Hospital de Burgos, Burgos, Spain Hospital de Granada, Granada, Spain Hospital Clinico Madrid, Madrid, Spain Hospital Zaragoza, Zaragoza, Spain Hospital Clinico Salamanca, Salamanca, Spain
    J Clin Oncol 27:6009. 2009
    ..2007;357:1705-1715). However, CRT alone is standard treatment for unresectable LAHNC. We designed a trial to compare two different regimens of IC followed by CRT versus CRT alone in pts with unresectable LAHNC...
  29. ncbi request reprint Occupational asthma caused by exposure to cyanoacrylate
    S Quirce
    , , Madrid, Spain
    Allergy 56:446-9. 2001
    ..CONCLUSION: Exposure to cyanoacrylate in these patients provoked not only variable airflow limitation and bronchial hyperresponsiveness, but also pronounced eosinophilia in sputum...
  30. pmc Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer
    J Sastre
    Medical Oncology Department, Clinic San Carlos University Hospital Center Affiliated with the Red Tematica de Investigacion Cooperativa en Cancer, Instituto Carlos III, Spanish Ministry of Science and Innovation, Calle Profesor Martín Lagos, S N, 28040, Madrid, Spain
    Clin Transl Oncol 16:942-53. 2014
    ..This review addresses practical aspects of its use, such as dosing, patient monitoring, and management of the most common regorafenib-related AEs...
  31. ncbi request reprint Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy
    M Martin
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain
    Eur J Cancer 28:430-2. 1992
    ..These data, together with other from the literature, should be taken into consideration when reviewing the overall results of current antiemetic trials, which usually only mention the results obtained in the first course of chemotherapy...
  32. ncbi request reprint Successful rectal cancer local recurrence radiofrequency ablation
    C Bueno Muiño
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain
    Clin Transl Oncol 10:300-2. 2008
    ..A local rectal cancer recurrence radiofrequency ablation is reported. PET scan confirmed the recurrence, defined the target volume and assessed the success of the local therapy...
  33. doi request reprint How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area
    J Sastre
    Allergy Department, Fundacion Jimenez Diaz, Madrid, Spain
    Allergy 67:709-11. 2012
    ..The aim of this study was to determine whether molecular diagnosis (MD) may change indication and allergen prescription of SIT...
  34. doi request reprint Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain
    C Gravalos
    Hospital 12 de Octubre, Madrid, Spain
    Clin Transl Oncol 13:862-8. 2011
    ..Capecitabine, after showing a trend in improved downstaging in neoadjuvant stratum and the convenience of its oral administration, represents an alternative to 5-FU as perioperative treatment of LARC...
  35. doi request reprint An odorant-binding protein as a new allergen from Siberian hamster (Phodopus sungorus)
    J A Torres
    Department of Allergy, Fundacion Jimenez Diaz, Av Reyes Catolicos 2, Madrid, Spain
    Int Arch Allergy Immunol 157:109-12. 2012
    ..The 3 bands likely correspond to isoforms of a single allergen...
  36. ncbi request reprint Immunotherapy with a Phleum pratense allergen extract induces an immune response to a grass-mix allergen extract
    C Martinez-Cocera
    Allergy Department, Hospital Clinico Universitario San Carlos, Madrid, Spain
    J Investig Allergol Clin Immunol 20:13-9. 2010
    ..Grass pollen allergy is one of the most common allergies worldwide, and patients often show sensitization to an array of phylogenetically related species...
  37. ncbi request reprint Circulating tumor cells in solid tumor in metastatic and localized stages
    Luisa M Maestro
    Servicio de Analisis Clinicos, Hospital Clinico San Carlos, 28040, Madrid, Espana
    Anticancer Res 29:4839-43. 2009
    ..The aim of this study was the detection of circulating tumor cells (CTC) in three tumor types of epithelial origin...
  38. ncbi request reprint Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Tri
    Eduardo Diaz-Rubio
    Department of Medical Oncology, Hospital Clinico Universitario San Carlos, Madrid, Spain
    J Clin Oncol 25:4224-30. 2007
    ....
  39. pmc Clinical guideline SEOM: hepatocellular carcinoma
    J Sastre
    Medical Oncology Department, Hospital Universitario Clinico San Carlos, Prof Martin Lagos, S N, 28040, Madrid, Spain
    Clin Transl Oncol 17:988-95. 2015
    ..Surgical interventions remain as the only curative procedures but both local and systemic approaches may increase survival and should be offered to patients without contraindications. ..
  40. ncbi request reprint Pharmacogenetic approach for capecitabine or 5-fluorouracil (5FU) selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer
    E Martinez-Balibrea
    Hospital Germans Trias i Pujol ICO Badalona, Badalona, Spain Hospital Reina Sofía, Cordoba, Spain Hospital Clínico San Carlos, Madrid, Spain Hospital Universitari la Fe, Valencia, Spain Hospital Morales Meseguer, Murcia, Spain Hospital Virgen de los Lirios, Alicancte, Spain Institut Català d Oncologia IDIBELL, L Hospitalet de Llobregat, Spain
    J Clin Oncol 26:4132. 2008
    ..The aim of this work was to study genetic polymorphisms and their role in tailoring fluroropyrimidine/oxaliplatin treatment in metastatic colorectal cancer (mCRC)...
  41. ncbi request reprint Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain
    J Feliu
    Medical Oncology Department, Hospital Universitario La Paz, Paseo de la Castellana, 261, 28046, Madrid, Spain
    Clin Transl Oncol . 2016
    ..The use of aflibercept outside the clinical trial framework needs to be further assessed in terms of effectiveness and tolerability...
  42. doi request reprint Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02
    F Rivera
    Servicio de Oncologia Medica, Hospital Universitario Marques de Valdecilla, 39008, Santander, Spain
    Cancer Chemother Pharmacol 75:319-24. 2015
    ..We defined "suboptimal" pts as those with PS ECOG = 2, weight loss 10-25% and/or age ≥70 years. This population is usually underrepresented in AGC clinical trials...
  43. doi request reprint A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer
    R Hitt
    Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid
    Ann Oncol 25:216-25. 2014
    ..This randomized, open-label, phase III clinical trial compared the efficacy between standard CCRT and two different induction chemotherapy (ICT) regimens followed by CCRT...
  44. doi request reprint Noninvasive methods for assessment of airway inflammation in occupational settings
    S Quirce
    Department of Allergy, Hospital La Paz, Madrid, Spain
    Allergy 65:445-58. 2010
    ..Key messages and suggestions on the use of noninvasive methods for assessment of airway inflammation in the investigation and diagnosis of occupational airway diseases are issued...
  45. ncbi request reprint Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study
    Emilio Fonseca
    Servicio de Oncologia Medica, Hospital Clinico Universitario, Paseo de San Vicente, 182, 37007 Salamanca, Spain
    Eur J Cancer 41:1254-60. 2005
    ..1%) and diarrhoea (9.8%) versus mucositis (29.3%) and neutropaenia (19.5%) in arm B. Both schedules present a similar efficacy, with different but acceptable toxicity patterns...
  46. ncbi request reprint Economic assessment of capecitabine/cisplatin versus 5-FU/cisplatin regimens in adjuvant treatment of advanced gastric cancer in Spain
    M Safont
    Hospital General Universitario de Valencia, Valencia, Spain Universitat de Barcelona, Barcelona, Spain BCN Health Economics and Outcomes Research, Barcelona, Spain Hospital Clínico San Carlos, Madrid, Spain Hospital del Mar, Barcelona, Spain Hospital Universitario Reina Sofía, Madrid, Spain C H Orense, Orense, Spain Roche Pharma, Madrid, Spain
    J Clin Oncol 26:15549. 2008
    ..6 months for XP versus 5.0 for FP) and response rates. An economic assessment was conducted in Spain to compare the costs of the two therapies taking into account unit costs and medical resource consumption for year 2007...
  47. ncbi request reprint Evaluation of the efficacy and the safety of lanreotide autogel 120 mg on tumor growth stabilization in patients with progressive neuroendocrine tumors (NETs) who are not eligible to surgery or chemotherapy
    M Martin-Richard
    Hospital de Sant Pau, Barcelona, Spain Hospital Miguel Servet, Zaragoza, Spain Hospital Clínic, Barcelona, Spain Hospital Universitario 12 de Octubre, Madrid, Spain Hospital Universitario, Salamanca, Spain Hospital Universitario de la Princesa, Madrid, Spain Hospital Ramon y Cajal, Madrid, Spain University Hospital Marqués de Valdecilla, Santander, Spain Hospital de Sagunto, Sagunto, Spain C H Juan Canalejo, A Coruna, Spain H Virgen de los Lirios, Alicante, Spain H de Basurto, Basurto, Spain Hospital Clínico San Carlos, Madrid, Spain H de la Candelaria, Canarias, Spain Hospital de Sabadell, Corporacio Sanitaria Parc Tauli, Sabadell, Spain La Fe University Hospital, Valencia, Spain H General Universitario, Alicante, Spain Ipsen, Barcelona, Spain Medical Oncology Alicante University Hospital, Alicante, Spain
    J Clin Oncol 29:e14660. 2011
    ..We undertook a phase II trial (NCT0032646) to evaluate the efficacy of lanreotide Autogel 120mg on tumour growth stabilisation in patients with documented progressive NETs...
  48. doi request reprint Occupational hypersensitivity pneumonitis: an EAACI position paper
    S Quirce
    Department of Allergy, Hospital La Paz Institute for Health Research IdiPAZ and CIBER de Enfermedades Respiratorias CIBERES, Madrid, Spain
    Allergy 71:765-79. 2016
    ..The cornerstone of treatment is early removal from exposure to the eliciting antigen, although the disease may show an adverse outcome even after avoidance of exposure to the causal agent. ..
  49. ncbi request reprint Effects of acute infusion of erythropoietin on paradoxical responses of growth hormone to thyrotropin-releasing hormone in acromegalic patients
    J J Diez
    Department of Endocrinology, Hospital La Paz, Madrid, Spain
    Eur J Endocrinol 143:203-11. 2000
    ..v. infusion of recombinant human erythropoietin (rhEPO) on the responses of growth hormone (GH), prolactin (PRL) and thyrotropin (TSH) to thyrotropin-releasing hormone (TRH) stimulation in acromegalic patients...
  50. doi request reprint Molecular diagnosis in allergy
    J Sastre
    Allergy Department, Fundacion Jimenez Diaz, Madrid, Spain
    Clin Exp Allergy 40:1442-60. 2010
    ..Nevertheless, all in vitro tests should be evaluated together with the clinical history, because allergen sensitization does not necessarily imply clinical responsiveness...
  51. doi request reprint Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register
    Javier Puente
    Medical Oncology Department, Hospital Clinico San Carlos, c Martin Lagos s n, 28040, Madrid, Spain
    Breast Cancer Res Treat 122:591-600. 2010
    ..61). The median survivals for these groups were 3.69, 2.27 and 1.02 years, respectively (P < 0.0001). In conclusion, risk scores are extraordinarily valuable tools, highly recommendable in the clinical practice...
  52. ncbi request reprint Circulating tumor cells in metastatic breast cancer: timing of blood extraction for analysis
    Miguel Martin
    Medical Oncology Service, Hospital Universitario San Carlos, Madrid, Spain
    Anticancer Res 29:4185-7. 2009
    ....
  53. ncbi request reprint Significance of the immunohistochemical detection of lymph node micrometastases in stage II colorectal carcinoma
    José A García-Sáenz
    Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 8:676-80. 2006
    ..Immunohistochemistry is being explored to detect undetectable microscopic lymph node micrometastases...
  54. doi request reprint Irinotecan in the treatment of elderly patients with advanced colorectal cancer
    Javier Sastre
    Medical Oncology Department, San Carlos Hospital, c Martin Lagos s n, 28040 Madrid, Spain
    Crit Rev Oncol Hematol 68:250-5. 2008
    ..This revision has been focused in the role of irinotecan in elderly patients...
  55. doi request reprint Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
    E Grande
    Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid
    Ann Oncol 26:1987-93. 2015
    ..The management of advanced neuroendocrine tumors (NETs) has recently changed. We assessed the activity of pazopanib after failure of other systemic treatments in advanced NETs...
  56. ncbi request reprint Lack of allergic cross-reactivity to cephalosporins among patients allergic to penicillins
    A Novalbos
    Servicio de Alergia, , , , 28040 Madrid, Spain
    Clin Exp Allergy 31:438-43. 2001
    ....
  57. ncbi request reprint Occupational asthma and rhinitis caused by eugenol in a hairdresser
    S Quirce
    Fundacion Jimenez Diaz, Servicio de Alergia, Av Reyes Católicos, 2, 28040 Madrid, Spain
    Allergy 63:137-8. 2008
  58. doi request reprint Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study
    Xavier Garcia-Del-Muro
    Genitourinary Tumors and Sarcoma Unit, Department of Medical Oncology, Institut Català d Oncologia L Hospitalet, Barcelona, Spain
    J Clin Oncol 26:5416-21. 2008
    ..To assess the long-term efficacy and toxicity of front-line cisplatin-based chemotherapy in patients with stage IIA or IIB testicular seminoma...
  59. ncbi request reprint Circulating tumour cells in locally advanced breast cancer
    Jose Angel Garcia-Saenz
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain
    Clin Transl Oncol 11:544-7. 2009
    ..Two blood samples were obtained from 72 eligible LABC patients to isolate and enumerate CTCs before neoadjuvant chemotherapy started on day 1, and on day 21, immediately before second cycle administration...
  60. ncbi request reprint Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
    José A García-Sáenz
    Servicio de Oncologia Medica, Hospital Clinico Universitario San Carlos, Madrid, Spain
    Clin Transl Oncol 11:737-47. 2009
    ..Such patterns may be a novel and cost-effective tool to develop tailored treatments. This manuscript will review biomarkers and molecular pathways that are involved in the tumour response to anti-EGFR therapies...
  61. ncbi request reprint Cuirasse skin metastases secondary to gastric adenocarcinoma
    Sara López-Tarruella Cobo
    Servicio de Oncologia Medica, Hospital Clinico San Carlos, c Martin Lagos s n, 28040 Madrid, Spain
    Clin Transl Oncol 7:213-5. 2005
    ..We report, here, the case of a patient diagnosed with gastric adenocarcinoma with extensive subcutaneous infiltration of the abdominal wall, resulting in an abdominal cuirass...
  62. doi request reprint Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer
    Eva Martinez-Balibrea
    Medical Oncology Service, Hospital Universitari Germans Trias i Pujol Institut Català d Oncologia, Badalona, Barcelona, Spain
    Eur J Cancer 44:1229-37. 2008
    ..006) were strong independent prognostic factors. According to this, patients harbouring TS-3'UTR +6bp/+6bp and ERCC1-118C/T or C/C genotypes may better receive capecitabine instead of 5FU in an oxaliplatin-based first-line treatment...
  63. ncbi request reprint Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors
    Axel R Hanauske
    Department of Medicine, Asklepios Hospital St Georg, D 20099 Hamburg, Germany
    Clin Cancer Res 13:523-31. 2007
    ..This trial assessed the maximum tolerated dose (MTD), safety, preliminary efficacy, and pharmacokinetics of erlotinib combined with FOLFOX...
  64. ncbi request reprint Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer
    Albert Abad
    Institut Catala d Oncologia, Hospital Germans Trias i Pujol, Ctra Canyet, s n 08916 Badalona, Barcelona, Spain
    Clin Colorectal Cancer 4:384-9. 2005
    ..9% and 16.7%). Biweekly oxaliplatin in combination with nonmodulated high-dose 5-FU is an active, well-tolerated treatment that offers a lower cost than a modulated schedule for patients with advanced, metastatic CRC...
  65. ncbi request reprint [Detection and quantification of circulating tumor cells in peripheral blood in patients with colon cancer]
    Marta Vidaurreta
    Servicio de Analisis Clinicos, Hospital Clinico San Carlos, Madrid, Espana
    Med Clin (Barc) 129:333-4. 2007
    ..The aim of this study is the detection and quantification of circulating tumor cells (CTC) in patients diagnosed with colon cancer and to establish whether they are related to the main clinicopathologic variables for this type of carcinoma...
  66. ncbi request reprint Circulating tumoral cells lack circadian-rhythm in hospitalized metastasic breast cancer patients
    Jose Angel Garcia-Saenz
    Servicio de Oncología Médica Hospital Universitario San Carlos Madrid Spain
    Clin Transl Oncol 8:826-9. 2006
    ..The relationship between breast cancer and circadian rhythm variation has been extensively studied. Increased breast tumorigenesis has been reported in melatonin-suppressed experimental models and in observational studies...
  67. ncbi request reprint Glutathione S-transferases mu 1, theta 1, pi 1, alpha 1 and mu 3 genetic polymorphisms and the risk of colorectal and gastric cancers in humans
    Carmen Martinez
    Department of Pharmacology and Psychiatry, University of Extremadura, Badajoz, Spain
    Pharmacogenomics 7:711-8. 2006
    ..This study aimed to elucidate the influence of several GST polymorphisms on colorectal and gastric cancer risk...